Literature DB >> 8636263

New mutations of DAX-1 genes in two Japanese patients with X-linked congenital adrenal hypoplasia and hypogonadotropic hypogonadism.

T Yanase1, R Takayanagi, K Oba, Y Nishi, K Ohe, H Nawata.   

Abstract

Congenital adrenal hypoplasia, an X-linked disorder, is characterized by primary adrenal insufficiency and frequent association with hypogonadotropic hypogonadism. The X-chromosome gene DAX-1 has been most recently identified and shown to be responsible for this disorder. We analyzed the DAX-1 genes of two unrelated Japanese patients with congenital adrenal hypoplasia and hypogonadotropic hypogonadism by using PCR amplification of genomic DNA and its complete exonic sequencing. In a family containing several affected individuals, the proband male patient had a stop codon (TGA) in place of tryptophan (TGG) at amino acid position 171. As expected, his mother was a heterozygous carrier for the mutation, whereas his father and unaffected brother did not carry this mutation. In another male patient with noncontributory family history, sequencing revealed a 1-bp (T) deletion at amino acid position 280, leading to a frame shift and, subsequently a premature stop codon at amino acid position 371. The presence of this mutation in the patients' genome was further confirmed by digestion of genomic PCR product with MspI created by this mutation. Family studies using MspI digestion of genomic PCR products revealed that neither parent of this individual carried the mutation. These results clearly indicate that congenital adrenal hypoplasia and hypogonadotropic hypogonadism result from not only inherited but also de novo mutation in the DAX-1 gene.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8636263     DOI: 10.1210/jcem.81.2.8636263

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  DAX-1 inhibits SF-1-mediated transactivation via a carboxy-terminal domain that is deleted in adrenal hypoplasia congenita.

Authors:  M Ito; R Yu; J L Jameson
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

Review 2.  Hypogonadotropic hypogonadism in subjects with DAX1 mutations.

Authors:  Unmesh Jadhav; Rebecca M Harris; J Larry Jameson
Journal:  Mol Cell Endocrinol       Date:  2011-06-13       Impact factor: 4.102

3.  DAX1 mutations map to putative structural domains in a deduced three-dimensional model.

Authors:  Y H Zhang; W Guo; R L Wagner; B L Huang; L McCabe; E Vilain; T P Burris; K Anyane-Yeboa; A H Burghes; D Chitayat; A E Chudley; M Genel; J M Gertner; G J Klingensmith; S N Levine; J Nakamoto; M I New; R A Pagon; J G Pappas; C A Quigley; I M Rosenthal; J D Baxter; R J Fletterick; E R McCabe
Journal:  Am J Hum Genet       Date:  1998-04       Impact factor: 11.025

Review 4.  Evolutionary conservation and expression of human RNA-binding proteins and their role in human genetic disease.

Authors:  Stefanie Gerstberger; Markus Hafner; Manuel Ascano; Thomas Tuschl
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

5.  A novel mutation in DAX1 causes delayed-onset adrenal insufficiency and incomplete hypogonadotropic hypogonadism.

Authors:  A Tabarin; J C Achermann; D Recan; V Bex; X Bertagna; S Christin-Maitre; M Ito; J L Jameson; P Bouchard
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

6.  Analysis of DAX1 (NR0B1) and steroidogenic factor-1 (NR5A1) in children and adults with primary adrenal failure: ten years' experience.

Authors:  Lin Lin; Wen-Xia Gu; Gokhan Ozisik; Wing S To; Catherine J Owen; J Larry Jameson; John C Achermann
Journal:  J Clin Endocrinol Metab       Date:  2006-05-09       Impact factor: 5.958

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.